Navigation Links
Press Statement: Roche Affirms That Tamiflu(R) is in Ample Supply Nationwide
Date:2/19/2008

NUTLEY, N.J., Feb. 19 /PRNewswire/ -- In response to recent media reports, Roche would like to reaffirm that there is ample supply of Tamiflu(R) (oseltamivir phosphate) antiviral medication for the 2007-2008 flu season, and that physicians and patients can feel confident the drug is on hand if flu strikes.

Some news reports have indicated "shortages" of the product at retail, but Roche has special measures in place to ensure that Tamiflu is readily available. If a pharmacy runs low due to high demand during peak flu season, and they can't get product from their servicing wholesaler(s), they can call 800-526-0625 and have Tamiflu delivered within 24 hours.

Due to widespread flu activity throughout the U.S., there has been an increase in the number of prescriptions being written for Tamiflu during the past few weeks. For the week ending February 9, the Centers for Disease Control and Prevention (CDC) cited 49 states reporting either widespread or regional flu activity.

The CDC web site suggests a "Take 3" approach against flu:

1. Take time to get a vaccine.

2. Take everyday actions to stop germs.

3. Take antiviral drugs if your doctor says you need them.

The CDC recommends that antiviral medications oseltamivir (Tamiflu) or zanamivir (Relenza(R)) can be used for the treatment and prevention of flu in the U.S. this season.

Tamiflu is a prescription antiviral medication that attacks the flu virus at its source, so patients can get better faster. Tamiflu is available as a capsule or liquid suspension formula, both of which are in sufficient supply. For optimal effectiveness, Tamiflu must be taken within 48 hours of the onset of flu symptoms, which include sore throat, extreme fatigue and sudden high fever. If patients experience these symptoms, they should contact a physician for accurate diagnosis and treatment, even if they have been vaccinated.

Tamiflu is Effective Against Seasonal Flu

Tamiflu is designed to be effective against all A and B strains of influenza. The CDC reported Friday that there are three primary viral types circulating in the U.S. this year -- two A strains (H1N1 and H3N2) and numerous B strains. The A strain H3N2 is the predominant virus for the season overall, and is typically associated with more severe illness.

The vaccine is not optimally matched to the H3N2 or the B viruses, according to the CDC report. The vaccine does appear to be well-matched against the H1N1. During this season, there has been a small increase observed in the number of H1N1 viruses resistant to Tamiflu, but no resistance has been identified among the H3N2 and B viruses. Tamiflu is not a substitute for an annual flu shot.

For more details and full prescribing information, please visit http://www.tamiflu.com.


'/>"/>
SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. As depression symptoms improve with antidepressants, hopelessness can linger
2. Optimal band imaging with endoscopy facilitates the diagnosis of depressed-type early gastric cancer
3. American Chemical Societys Weekly PressPac -- Feb. 13, 2008
4. Cleveland Clinic Press Consumer Health Book Empowers and Gives Hope to People with Epilepsy
5. Blood pressure drug may have added benefit
6. Oncoproteins double-team and destroy vital tumor-suppressor
7. Male births are more likely to reduce quality of life and increase severe post-natal depression
8. Airplane Noise Boosts Blood Pressure Even During Sleep
9. Cleveland Clinic Press Releases Book About a Surgeons Mission to Perform the Worlds First Full Face Transplant
10. High blood pressure worsening in all states for women; begins to stagnate for men
11. Most With High Blood Pressure Dont Follow Recommended Diet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2017)... ... July 25, 2017 , ... ... provider in the United States, today announced its partnership with financial technology company, ... , The foundation of the solution lies within Hyosung’s superior ATMs, assisted self-service ...
(Date:7/24/2017)... , ... July 24, 2017 , ... Engineers at the ... because it produces the same kind of electrical energy that the body uses. ... of moving electrons. This flow of electrons out of the battery is generated by ...
(Date:7/24/2017)... , ... July 24, 2017 , ... ... federal Substance Abuse and Mental Health Services Administration’s (SAMHSA) State Targeted Response to ... Department of Health Care Services, will facilitate the development of a hub and ...
(Date:7/24/2017)... ... 2017 , ... Every year, thousands of dedicated Higher Education and K12 professionals ... is coupled with a dynamic theme like Camp Canvas; this year, they’ve managed to ... , To extend their partnership with Canvas beyond the LMS integration, Modo Labs ...
(Date:7/24/2017)... Solana Beach, California (PRWEB) , ... July 24, ... ... and commercialization of autologous fat (adipose) transfer systems announces the issuance of United ... (the ‘324 patent) for its adipose filtration technology. The '398 and '324 ...
Breaking Medicine News(10 mins):
(Date:7/24/2017)... 24, 2017 IBM (NYSE: IBM ) has ... for Solid-State Arrays (SSA) for the fourth year in a ... to Gartner, "Vendors in the Leaders quadrant have the highest ... A vendor in the Leaders quadrant has the market share, ... acceptance of new technologies. These vendors demonstrate a clear understanding ...
(Date:7/21/2017)... Did you know that PhRMA member companies invested $65.5 ... spending on brand medicines, generics and the supply chain account for ... just half of this (7 percent)? Or that the ... venture capital investments in high-growth biopharmaceutical startups? ... The biopharmaceutical ...
(Date:7/14/2017)... 14, 2017 Endo International plc (NASDAQ: ENDP ... 8, 2017.  Members of its senior management team will host a ... 8:30 a.m. ET. The dial-in number to access ... (678) 509-7598, and the passcode is 45397076. Please dial in 10 ... A replay of the call will be available ...
Breaking Medicine Technology: